Efficacy and safety of once‐weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the <scp>SURMOUNT</scp> ‐2 trial
In Japanese adults with obesity and T2D, once-weekly treatment with tirzepatide (10 or 15 mg) demonstrated significant reductions in body weight compared with placebo, with the safety profile generally consistent with previous studies.
Authors
- Hideki Katagiri (ORCID: https://orcid.org/0000-0003-1093-3704)
- Toshimasa Yamauchi (ORCID: https://orcid.org/0000-0003-4827-6404)
- Tomotaka Shingaki (ORCID: https://orcid.org/0000-0003-1568-9763)
- Tomonori Oura (ORCID: https://orcid.org/0000-0003-0872-8576)
- Taro Asakura
Institutions
- Tohoku University (JP)
- Diabetes Australia (AU)
- Eli Lilly (Japan) (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1111/dom.16500
- Citations
- 3
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- Eli Lilly and Company
- Eli Lilly Japan